Transmitted resistance to HIV integrase strand-transfer inhibitors: Right on schedule

Antiviral Therapy

Volumn 16, Issue 2, 2011, Pages 137-140

  Hurt, Christopher B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; INTEGRASE INHIBITOR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; SEROCONVERSION; TRANSMITTED DRUG RESISTANCE; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; PREVALENCE; UNITED STATES;

EID: 79953200796     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1750     Document Type: Note

References (37)

1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-529.
2. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010; 24:1203-1212.
3. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82:5510-5518. (Pubitemid 351705258)
4. Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D. Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 2009; 83:2645-2654.
5. Smith DM, Wong JK, Shao H, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 2007; 196:356-360. (Pubitemid 47093885)
6. CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20:21-28.
7. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55:39-48.
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 1 December 2009. Department of Health and Human Services. (Accessed 3 January 2011.) Available from http://www.aidsinfo.nih.gov/ contentfiles/ AdultandAdolescentGL001419.pdf
9. Rhee SY, Liu TF, Kiuchi M, et al. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008; 5:74.
10. Ceccherini-Silberstein F, Malet I, Fabeni L, et al. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother 2010; 65:2305-2318.
11. Young B, Fransen S, Greenberg KS, et al. Transmission of integrase strand-transfer inhibitor multidrug resistant HIV-1: case report and natural history of response to raltegravir-containing antiretroviral therapy. Antivir Ther 2011; doi:10.3851/IMP1748.
12. Boyd S, Maldarelli F, Sereti I, et al. Transmitted raltegravir resistance in an HIV-1 CRF-AG-infected patient. Antivir Ther 2011; doi:10.3851/IMP1749.
13. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993; 328:1163-1165. (Pubitemid 23105754)
14. Mayers DL, Yerly S, Perrin L, et al. Prevalence and clinical course of persons seroconverting with AZT-resistant (AZTR) HIV-1 in Switzerland, Australia, and the United States between 1988 and 1994. AIDS Res Hum Retroviruses 1995; 11 Suppl 1:S162.
15. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354:729-733. (Pubitemid 29407396)
16. Rubio A, Leal M, Pineda JA, et al. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996. AIDS 1997; 11:1184-1186.
17. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993; 37:178-182. (Pubitemid 23046550)
18. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997; 175:1502-1506. (Pubitemid 27225058)
19. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188. (Pubitemid 34755278)
20. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339:307-311. (Pubitemid 28366419)
21. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345:952-955.
22. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394. (Pubitemid 34851830)
23. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
24. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 2010; 5:e11068.
25. Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 38:b1649.
26. Bartmeyer B, Kuecherer C, Houareau C, et al. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS ONE 2010; 5:e12718.
27. Vercauteren J, Wensing AM, van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200:1503-1508.
28. Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect 2003; 79:59-61. (Pubitemid 36237829)
29. Flaks RC, Burman WJ, Gourley PJ, Rietmeijer CA, Cohn DL. HIV transmission risk behaviour and its relation to antiretroviral treatment adherence. Sex Transm Dis 2003; 30:399-404. (Pubitemid 36605488)
30. Kozal MJ, Amico KR, Chiarella J, et al. Antiretroviral resistance and high-risk transmission behaviour among HIV-positive patients in clinical care. AIDS 2004; 18:2185-2189. (Pubitemid 39463684)
31. Napravnik S, Zakharova OM, McKaig RG, et al. High risk for transmission of HIV and antiretroviral drugresistant HIV variants among HIV-infected patients in care. 3rd International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract MoPp0203.
32. Chin-Hong PV, Deeks SG, Liegler T, et al. High-risk sexual behaviour in adults with genotypically proven antiretroviral-resistant HIV infection. J Acquir Immune Defic Syndr 2005; 40:463-471. (Pubitemid 41669182)
33. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 327:575-580. (Pubitemid 16138382)
34. US Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection. (Updated 6 January 2010. Accessed 6 January 2011.) Available from http://www. fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ HIVandAIDSActivities/ucm118915.htm
35. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-1307. (Pubitemid 28512112)
36. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-515. (Pubitemid 44885615)
37. Peuchant O, Capdepont S, Ragnaud JM, et al. Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir Ther 2007; 12:559-562.